Takeda Highlights Pioglitazone Fracture Risk In "Dear Healthcare Provider" Letter
This article was originally published in PharmAsia News
Executive Summary
Takeda is notifying healthcare providers there is an increased risk of fracture in women taking pioglitazone drugs for treatment of type 2 diabetes, according to a March 9 FDA MedWatch alert. The alert marks the second time in several weeks the agency has cautioned doctors regarding thiazolidinediones (TZDs) and fracture risk